MOLN vs DMF Comparison

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.